230 related articles for article (PubMed ID: 20068551)
1. Nanoparticles targeted with NGR motif deliver c-myc siRNA and doxorubicin for anticancer therapy.
Chen Y; Wu JJ; Huang L
Mol Ther; 2010 Apr; 18(4):828-34. PubMed ID: 20068551
[TBL] [Abstract][Full Text] [Related]
2. Multifunctional nanoparticles delivering small interfering RNA and doxorubicin overcome drug resistance in cancer.
Chen Y; Bathula SR; Li J; Huang L
J Biol Chem; 2010 Jul; 285(29):22639-50. PubMed ID: 20460382
[TBL] [Abstract][Full Text] [Related]
3. Co-delivery of CPP decorated doxorubicin and CPP decorated siRNA by NGR-modified nanobubbles for improving anticancer therapy.
Ma R; Nai J; Zhang J; Li Z; Xu F; Gao C
Pharm Dev Technol; 2021 Jul; 26(6):634-646. PubMed ID: 33843423
[TBL] [Abstract][Full Text] [Related]
4. A self-assembled polyjuglanin nanoparticle loaded with doxorubicin and anti-Kras siRNA for attenuating multidrug resistance in human lung cancer.
Wen ZM; Jie J; Zhang Y; Liu H; Peng LP
Biochem Biophys Res Commun; 2017 Dec; 493(4):1430-1437. PubMed ID: 28958938
[TBL] [Abstract][Full Text] [Related]
5. Dual-modified liposomes with a two-photon-sensitive cell penetrating peptide and NGR ligand for siRNA targeting delivery.
Yang Y; Yang Y; Xie X; Wang Z; Gong W; Zhang H; Li Y; Yu F; Li Z; Mei X
Biomaterials; 2015 Apr; 48():84-96. PubMed ID: 25701034
[TBL] [Abstract][Full Text] [Related]
6. Cell-penetrating peptide-doxorubicin conjugate loaded NGR-modified nanobubbles for ultrasound triggered drug delivery.
Lin W; Xie X; Deng J; Liu H; Chen Y; Fu X; Liu H; Yang Y
J Drug Target; 2016; 24(2):134-46. PubMed ID: 26176270
[TBL] [Abstract][Full Text] [Related]
7. Binding and internalization of NGR-peptide-targeted liposomal doxorubicin (TVT-DOX) in CD13-expressing cells and its antitumor effects.
Garde SV; Forté AJ; Ge M; Lepekhin EA; Panchal CJ; Rabbani SA; Wu JJ
Anticancer Drugs; 2007 Nov; 18(10):1189-200. PubMed ID: 17893520
[TBL] [Abstract][Full Text] [Related]
8. Novel functionalized nanoparticles for tumor-targeting co-delivery of doxorubicin and siRNA to enhance cancer therapy.
Xia Y; Xu T; Wang C; Li Y; Lin Z; Zhao M; Zhu B
Int J Nanomedicine; 2018; 13():143-159. PubMed ID: 29317822
[TBL] [Abstract][Full Text] [Related]
9. Sequential treatment of drug-resistant tumors with RGD-modified liposomes containing siRNA or doxorubicin.
Jiang J; Yang SJ; Wang JC; Yang LJ; Xu ZZ; Yang T; Liu XY; Zhang Q
Eur J Pharm Biopharm; 2010 Oct; 76(2):170-8. PubMed ID: 20600887
[TBL] [Abstract][Full Text] [Related]
10. Novel cationic lipid that delivers siRNA and enhances therapeutic effect in lung cancer cells.
Chen Y; Sen J; Bathula SR; Yang Q; Fittipaldi R; Huang L
Mol Pharm; 2009; 6(3):696-705. PubMed ID: 19267451
[TBL] [Abstract][Full Text] [Related]
11. PEGylated liposomes with NGR ligand and heat-activable cell-penetrating peptide-doxorubicin conjugate for tumor-specific therapy.
Yang Y; Yang Y; Xie X; Cai X; Zhang H; Gong W; Wang Z; Mei X
Biomaterials; 2014 May; 35(14):4368-81. PubMed ID: 24565519
[TBL] [Abstract][Full Text] [Related]
12. Novel Class of Ultrasound-Triggerable Drug Delivery Systems for the Improved Treatment of Tumors.
Zhou C; Xie X; Yang H; Zhang S; Li Y; Kuang C; Fu S; Cui L; Liang M; Gao C; Yang Y; Gao C; Yang C
Mol Pharm; 2019 Jul; 16(7):2956-2965. PubMed ID: 31084010
[TBL] [Abstract][Full Text] [Related]
13. Enhanced small interfering RNA delivery into cells by exploiting the additive effect between photo-sensitive peptides and targeting ligands.
Lin W; Xie X; Yang Y; Liu H; Fu X; Chen Y; Liu H; Yang Y
J Pharm Pharmacol; 2015 Sep; 67(9):1215-31. PubMed ID: 25880614
[TBL] [Abstract][Full Text] [Related]
14. Intratracheal versus intravenous liposomal delivery of siRNA, antisense oligonucleotides and anticancer drug.
Garbuzenko OB; Saad M; Betigeri S; Zhang M; Vetcher AA; Soldatenkov VA; Reimer DC; Pozharov VP; Minko T
Pharm Res; 2009 Feb; 26(2):382-94. PubMed ID: 18958402
[TBL] [Abstract][Full Text] [Related]
15. Targeted nanoparticles deliver siRNA to melanoma.
Chen Y; Bathula SR; Yang Q; Huang L
J Invest Dermatol; 2010 Dec; 130(12):2790-8. PubMed ID: 20686495
[TBL] [Abstract][Full Text] [Related]
16. Characterization and application of a nose-only exposure chamber for inhalation delivery of liposomal drugs and nucleic acids to mice.
Mainelis G; Seshadri S; Garbuzenko OB; Han T; Wang Z; Minko T
J Aerosol Med Pulm Drug Deliv; 2013 Dec; 26(6):345-54. PubMed ID: 23530772
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the potential of a simplified co-delivery system with oligodeoxynucleotides as a drug carrier for enhanced antitumor effect.
Liu C; Liu T; Liu Y; Zhang N
Int J Nanomedicine; 2018; 13():2435-2445. PubMed ID: 29719392
[TBL] [Abstract][Full Text] [Related]
18. Doxorubicin and siRNA-PD-L1 co-delivery with T7 modified ROS-sensitive nanoparticles for tumor chemoimmunotherapy.
Wan WJ; Qu CX; Zhou YJ; Zhang L; Chen MT; Liu Y; You BG; Li F; Wang DD; Zhang XN
Int J Pharm; 2019 Jul; 566():731-744. PubMed ID: 31212055
[TBL] [Abstract][Full Text] [Related]
19. Nanoparticles evading the reticuloendothelial system: role of the supported bilayer.
Li SD; Huang L
Biochim Biophys Acta; 2009 Oct; 1788(10):2259-66. PubMed ID: 19595666
[TBL] [Abstract][Full Text] [Related]
20. Surface-modified LPD nanoparticles for tumor targeting.
Li SD; Huang L
Ann N Y Acad Sci; 2006 Oct; 1082():1-8. PubMed ID: 17145918
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
